X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
May 6, 2021 8:00 AM EDTCompany continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications
Enrollment update on Phase 3 WHIM trial expected in mid-2021
Initial data from ongoing Phase 1b trial in Waldenströms macroglobulinemia to be presented at EHA Meeting in June 2021
Conference call today at 8:30 a.m. ET
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:... More
